Table 1. Baseline characteristics of the trial participants.
| Text (n = 150) | No Text (n = 151) | |||
| Median age (interquartile range) | 60 | (54–68) | 61 | (49–69) |
| Male (%) | 82 | (55) | 81 | (54) |
| Smoker (%) | 24 | (16) | 27 | (18) |
| Medical history | ||||
| Diabetes (%) | 44 | (29) | 55 | (36) |
| Myocardial Infarction (%) | 15 | (10) | 14 | (9) |
| Stroke (%) | 10 | (7) | 10 | (7) |
| CABG (%) | 6 | (4) | 5 | (3) |
| Angioplasty (%) | 14 | (9) | 17 | (11) |
| Drugs | ||||
| Cholesterol lowering (%) | 102 | (68) | 117 | (77) |
| Statin (%) | 101 | (67) | 115 | (76) |
| Fibrate (%) | 1 | (1) | 3 | (2) |
| Blood pressure lowering (%) | 102 | (68) | 101 | (67) |
| ACE inhibitor (%) | 51 | (34) | 59 | (39) |
| ARB (%) | 11 | (7) | 20 | (13) |
| CCB (%) | 55 | (37) | 60 | (40) |
| Beta blocker (%) | 19 | (13) | 22 | (15) |
| Alpha blocker (%) | 6 | (4) | 9 | (6) |
| Diuretic (%) | 33 | (23) | 34 | (23) |
| Cholesterol and BP lowering (%) | 54 | (36) | 67 | (44) |
ACE - Angiotensin converting enzyme, ARB - Angiotensin Receptor Blocker, CCB – Calcium channel blocker